Arch Biopartners Inc ACHFF

Primary Symbol: V.ARCH

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Tax Loss Selling

<< Previous

Bullboard Posts

Next >>

Post by Arbourmarkon Dec 07, 2022 3:53pm

150 Views

Post# 35157316

Tax Loss Selling

Above average volume on both US side and Canadian. Close to 50,000 shares sold.

I suspect that many purchased shares at higher price but with no news or updates in past 9 months has investors concerned and feel their investment is dead money. They will sell to take advantage of tax loss to offset gains in other holdings.

This is disappointing to see this name down 6% on no news and literally there is no news!

Let's assume that ARCH is planning new trials and will need to either raise capital or potentially a strategic partnership but at $2.80 per share valuation and $175M market cap.

<< Previous

Bullboard Posts

Next >>

Rock Tech notches official permit for German lithium refinery